Zoetis breaks ground on global manufacturing, supply, R&D complex in China

Suzhou, China
The new innovation and manufacturing facility will include 43,000 square meters of vaccine manufacturing operations and laboratory space. (Christian Gänshirt/CC BY-SA 4.0)

Pfizer animal health spinoff Zoetis officially broke ground for its combo complex in Suzhou, China, that will house a global manufacturing, supply and research and development center.

The new innovation and manufacturing facility will include 43,000 square meters of vaccine manufacturing operations and laboratory space. Construction is expected to be completed and the plant certified by Chinese authorities by 2021.

The cost of the project hasn’t been disclosed. Zoetis reported revenue of $174 million in China in 2017. The company began operations in China in 1995 and has approximately 600 employees and commercial headquarters in Shanghai. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

“With this new center for vaccine innovation co-located with expanded manufacturing capabilities in Suzhou, and a team of highly trained field representatives, we are well-positioned to help China’s livestock farmers answer increasing demand for a safe and abundant supply of pork, milk, beef and fish,” Mike Wang, SVP for Zoetis in China, said in a statement.

When completed, the facility in Suzhou will focus on development and production of vaccines for swine, cattle, fish and companion animals in China. According to Vetnosis, China is the world’s second largest animal health market, valued at $4.3 billion in 2017. 

In 2015, Zoetis acquired aquatic vaccine maker Pharmaq for $765 million. A year later it paid $85 million for Nexvet, which develops species-specific monoclonal antibodies to treat osteoarthritis pain and other disorders in companion animals.

Read more on

Suggested Articles

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico. 

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.